BioSpace News Archive

Milestone Pharmaceuticals Inc. today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022 in Chicago, IL and virtually.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO).

Soligenix, Inc. announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the Phase 2a clinical development of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.

Modifi Biosciences has been selected by the National Cancer Institute for a Fast-Track Small Business Innovation Research Award of $2.4 million to further advance its novel precision oncology platform into the clinic.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022.

Hospital for Special Surgery announced a $21M Series A to launch RightMove Powered by HSS™, an independent for-profit company, whose mission is to make high quality, patient-focused virtual musculoskeletal physical therapy available to all Americans.

Almaden Genomics has launched g.nome™, a cloud-native platform designed to streamline genomic workflows and accelerate genomic discovery.

Researchers at the UCSF QBI Coronavirus Research Group have uncovered how the SARS-CoV-2 variants of concern differ in their ability to manipulate human cells on a molecular level during infection.

Neuronetics, Inc. announced healthcare policy updates that increase patient access to NeuroStar Advanced Therapy for Mental Health transcranial magnetic stimulation (TMS).

Enspectra Health, a digital health company pioneering the field of virtual biopsies, announced that the first subject has been enrolled in its VISTA US Pivotal Study. VIO™ Imaging for Skin Tissue Assessment (VISTA) is a prospective, multicenter study designed to demonstrate the safety and effectiveness of the VIO System.